2[2]Festa A,Dagostino R Jr,Howard G,et al.Chronic subclinical inflammation as part of the insulin resistance syndrome:the Insulin Resistance Atherosclerosis Study(IRAS).Circulation 2000,102:42-47.
3[3]Rosenson RS,Tangney CC.Antiatherothrombotic properties of statins:implications for cardiovascular event reduction.JAMA,1998,279:1643-1650.
4Temelkova-Kurktschiev T, Henkel E, Schaper F, et al. Prevalence and atherosclerosis risk in different types of non-diabetic hyperglycemia. Is mild hyperglycemia and underestimated evil? Exp Clin Endocrinol Diabetes, 2000,108:93-99.
5Haidari M, Javadi E, Sadeghi B, et al. Evaluation of C-reactive protein, a sensitive marker of inflammation, as a risk factor for stable coronary artery disease. Clin Biochem, 2001,33:309-315.
6Stern MP. Diabetes and cardiovascular disease: the "common soil" hypothesis. Diabetes, 1995,44:369-374.
7Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly. Diabetes, 2001,50:2384-2388.
8Verma S, Li SH, Badiwada MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation, 2002,105:1890-1896.
9Dandona P, Aliada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and athelosclerosis. Am J Cardiol, 2002,90:27G-33G.
10Pickup JC, Crook MA. Is type Ⅱ diabetes mellitus a disease of the innate immune system? Diabetologia, 1998,41:1241-1248.
